Dogwood Therapeutics, Inc.

  • About
    • Corporate Profile
    • Leadership
    • Board of Directors
    • Corporate Presentation
  • Technology
    • NaV 1.7
    • Antiviral Combination
  • Diseases
    • CINP
    • Long Covid
    • Fibromyalgia
  • Pipeline
  • Clinical Trials
    • CINP 203
  • Investors
  • News

Events

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • Events
    • Presentations
    • Shareholder Letters
    • Meeting
  • Governance
    • Overview
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • IR Contacts
    • FAQ
    • Email Alerts

  • Events & Presentations

  • Events
  • Presentations
  • Shareholder Letters
  • Meeting

Q2 2023 Financial Results and Corporate Update Call

Aug 10, 2023 8:30 am EST
Earnings Release
PDF HTML
Audio
Earnings Webcast
10-Q Filing
PDF HTML
XBRL
ZIP XLS HTML
Q2 2023 Earning Update with Long-COVID Data Summary
PDF
  • Email Alerts
  • Contacts
  • RSS News Feed

© 2024 Dogwood Therapeutics, Inc.           Terms and Conditions Privacy Policy Social Media Guidelines